Evaluation of herb-drug interactions of xanthophylls and fermented Ginseng extract focused on inhibitory effects of human hepatic cytochrome P450s and UDP-glucuronyltransferases by 정옥분
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activities as antioxidants, their roles in preventing cancer or







object was to investigate the herb-drug interactions of five
xanthophylsandBST204oninhibitionofhumanhepaticcytochrome
P450s (CYP1A2,CYP2A6,CYP2B6,CYP2C8,CYP2C9,CYP2C19,
CYP2D6,CYP2E1 and CYP3A4/5)and UDP-gluronosyltransferases
(UGT1A1,UGT1A4,UGT1A6,UGT1A9,UGT2B7)in human liver
microsomes.We also firstexplore the stereo selective effects of
ginsenosideRg3andRh2emipers(R-Rg3,S-Rg3,R-Rh2andS-Rh2)





and midazolam (5 μM)were chosen as substrates ofCYP1A2,
CYP2A6,CYP2B6,CYP2C8,CYP2C9,CYP2C19,CYP2D6,CYP2E1
and CYP3A,respectively.Cocktails,testcompounds and NADPH
re-generating system wereincubated 15min after5pre-incubation
with human liver microsomes (HLMs) in vitro for competitive
screening.Time-dependentinhibition (TDI)experiments were also
executed. The xanthophls, HLMs with/without NADPH were






mM Tris-HClbuffer (pH 7.5),MgCl2 (5 mM),substrate,and
alamethicin (25 μg/mL) were pre-incubated on ice to alow


















drugs metabolized by CYPs.In addition,theinhibitory effects of
xanthophylsonUGTswereignorableduetothemuchhigherIC50or


























































substrate reaction. Represented by % of control activity. Al
experimentswereconductedasduplicate.
Figure9.(A)Lineweaver-Burkplotand(B)DixonplotabouttheKi
determination of β-cryptoxanthin towards UGT1A1-mediated
glucuronidation.Altheexperimentswerecarriedoutinduplicate.
Figure 10.Dixon plotand Lineweaver-Burk plotaboutthe Ki
determinationofBST204towardsUGT-mediatedglucuronidation.(A)
BST204onUGT1A1-mediatedestradiolglucuronidation;(B)BST204
on UGT1A9-mediated propofol glucuronidation; (C) BST204 on
UGT2B7-mediated zidovudine glucuronidation.Al the experiments
werecarriedoutinduplicate.
Figure 11.Dixon plotand Lineweaver-Burk plotaboutthe Ki
determination ofginsenoside Rg3 S-form towards UGT-mediated
glucuronidation.(A)GinsenosideRg3S-form on UGT1A9-mediated
estradiol glucuronidation; (B) Ginsenoside Rg3 S-form on









Although drug-drug interactions may be identified during drug
developmentandapproval,food/supplement-drug interactionsshould
notbeoverlooked.Naturalhealth products arebeing increasingly
widely used. Apart from an appraisal of product safety and
effectiveness,attention should bepaid to thepotentialthatthese














themain pigmentsin crustacean,salmonid,and otherfarmed fish
feed,hasbeenusedforprotectingorganismsagainstawiderangeof










widely used as a food color additive and is also included in
pharmaceuticaltabletsusedforphotosensitivedisordertreatmentsand
tanningpils(Lyanetal.,2001).Luteinandzeaxanthinaretwomajor
carotenoids in the human macula and retina (Bone etal.,1988;
Handelmanetal.,1988).Inthediet,darkgreenleafyvegetables,corn,
and egg yolk contain the highest concentrations of lutein
(Sommerburg etal.,1998).Zeaxanthin is found in corn,orange
pepper,oranges,andtangerines.Luteinandzeaxanthinareimportant
nutrients for the prevention ofage-related macular degeneration









23% increase in liver glutathione S-transferase activity in rats
(Gradeletetal.,1996).Inhumanhepatocytes,astaxanthinappearedto
induce CYP2B6 and CYP3A4 (Kistleretal.,2002).However,the

















and 20(S)ginsenosideRg3 and 20(R)and 20(S)ginsenosideRh2
(R-Rg3,S-Rg3,R-Rh2 and S-Rh2,Figure 2),which have been
showed anti-tumoreffects(Seo etal.,2005b,Yang etal.,2012).
Much research has been focused on the stereoselective
pharmacologicaleffects ofginsenoside Rg3 and Rh2 epimers.For
example,Weihas demonstrated that Rg3 was stereo specificin
antioxidant activities as Rf or mexhibited significantly higher
antioxidanteffectsthanSform (Weietal2012a);20(R)-Rg3hasmore
potentadjuvantactivitythan20(S)-Rg3relatedtostereospecificin
stimulation of the immune response (Weietal.,2012b);however,
20(S)-ginsenosideRg3showedantioxidative,anti-inflammatory,and
matrix metaloproteinaseinhibitory activitiesin culturedmammalian
cel lines (Shinetal.,2013);Only ginsenoside 20(R)-Rh2 showed
selectiveosteoclastgenesisinhibitoryactivitywithoutanycytotoxicity
(Lietal.,2010);20(S)-GinsenosideRh2againstdoxorubicin-induced
cardiotoxicity (Wang et al.,2012); Only ginsenoside 20(S)-Rh2




thatstructuralisomerism may also show differentimpactsduring
drugmetabolism.
The aim ofthe presentstudy is to investigate the herb-drug
7
Figure 2. (A)~(D). Chemical structures of ginsenoside Rg3

















human livermicrosomes from a mixed poolof50 donors were
purchased from BD Gentest(Woburn,MA,USA).Astaxanthin,β
-cryptoxanthin,lutein,β-nicotinamideadeninedinucleotidephosphate
(NADP), glucose-6-phosphate,glucose-6-phosphatedehydrogenase,
MgCl2, acetaminophen, chlorzoxazone, coumarin, dextrorphan,
diethyldithiocarbamate, furafyline, ketoconazole, monterukast,
paclitaxel, sulfaphenazole, S-mephenytoin, S-benzylnirvanol,






USA). Bupropion, dextromethorphan, 4’-hydroxymephenytoin,
7‑hydroxycoumarin,1’-hydroxychlorzoxazone,1’-hydroxymidazolam,
midazolam,6α-hydroxypaclitaxel,propofol,efavirenz,canthaxanthin,






Competitive inhibitory efects ofxanthophyls and fermented
GinsengextractninecytochromeP450enzymes
So-caled cocktailassays in which severalenzyme activities are
determined in paralelby liquid chromatography –tandem mass
spectrometry (LC-MS/MS) are particularly useful.The inhibitory




brief,the 90-µL incubation mixture,including pooled human liver
microsomes(finalconcentration0.25mg/mL),0.1M phosphatebuffer
(pH 7.4), each P450-selective substrates cocktail set (A set:
phenacetin,coumarin,paclitaxel,S-mephenytoin,dextromethorphan,
andmidazolam;Bset:bupropion,tolbutamide,andchlorzoxazone),and
test compounds was pre-incubated for 5 min at 37°C. Test
compoundsweredissolvedinDMSO anddilutedin0.1M phosphate
buffer (pH 7.4), to a final concentration of 0.5% DMSO.
ConcentrationsofP450-selectivesubstrateswereusedclosetotheir
reportedKmvalues(Yuanetal,2002):50mM phenacetin(CYP1A2),5
mM coumarin (CYP2A6),10 mM paclitaxel (CYP2C8),100mM
tolbutamide (CYP2C9),100mM S-mephenytoin (CYP2C19),5 mM
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dextromethorphan(CYP2D6),50mM chlorzoxazone(CYP2E1),and5
mM midazolam (CYP3A4/5).Al ofP450-selectivesubstrateswere
dissolved in methanoland serialy diluted with methanolto the
requiredconcentrations,andthesolventwassubsequentlyevaporated
under reduced pressure using an AES2010 SpeedVac (Thermo
ElectronCo.,Waltham,MA).Ontheotherhand,coumarindissolved
in methanol was added directly to the mixed tube (a final
concentrationof0.5% methanol)becauseofitslow solubilityin0.1M
phosphate buffer (pH 7.4). P450-selective substrates and their
concentrations,metabolites,andpositivecontrolwereshowninTable
2.
Thereaction wasstarted by adding a10-µL NADPH-generating
system (1.3mM NADP+,3.3mM glucose-6-phosphate,3.3mM MgCl2,
and 0.4unit/mL glucose-6-phosphatedehydrogenase).Thereaction
system (100µL,totalvolume)wasincubatedfor15minat37°Cina
shaking waterbath.Afterincubation,reactions were stopped by





mean valueswereused foranalysis.Additionaly identicalparalel
incubation samples containing known directCYP inhibitors were
includedaspositivecontrols.
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(Obach etal.2007).In brief,pooled human livermicrosomes (1
mg/mL)wereincubated with testcompoundsin theabsenceand













mM Tris-HClbuffer (pH 7.5),MgCl2 (5 mM),substrate,and
alamethicin (25 μg/mL) were pre-incubated on ice to alow
alamethicin pore formation in vitro for30 min.Incubations were











controls to evaluate the suitability ofthese experiments and to
comparetheirIC50valuestoUGT1A1,UGT1A4,UGT1A6,UGT1A9,
andUGT2B7,respectively.UGTssubstratesandtheirconcentrations,
metabolites,and positive controlwere shown in Table 2.Al
substrates and inhibitors used as positive controls are selected




Al P450-selective and UGTs substrates, their concentrations,
metabolitesandeachpositivecontrolwereshowninTable1.
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Enzymes Substrates Final 
Conc. 
Metabolites Positive   Control
CYP1A2 Phenacetin 50µM Acetaminophen Furafylline
CYP2A6 Coumarin 5µM Oh-coumarin Tranylcypromine
CYP2B6 Bupropion 50µM Oh-bupropion Triethylenethiophor
amide
CYP2C8 Rosiglitazone 1µM Oh-rosiglitazone Monterukast
CYP2C9 Tolbutamide 100µM Oh-tolbutamide Sulfaphenazole
CYP2C19 S-mephenytoin 100µM Oh-mephenytoin S-Benzylnirvanol
CYP2D6 Dextromethorphan 5µM Dextrorpan Quinidine
CYP2E1 Chlorzoxazone 50µM Oh-chlorzoxazone Diethyldithiocarbam
ate
CYP3A4/5 Midazolam 5µM Oh-midazolam Ketoconazole









UGT1A9 Propofol 100µM Propofol-O-Glucuronide Niflumic acid








and 2B7,S-Rg3 on UGT1A9 and UGT2B7 were conducted.The
experimentsforthedeterminationofKivaluesofUGT1A1-catalyzed
estradiol 3-glucuronidation reaction, UGT1A9-catalyzed propofol
glucuronidation and UGT2B7-catalyzed 3'-azido-3'-deoxythimidine
glucuronidationwereselectedastheprobereactions.Chrysin,niflumic
acid and efavirenz were included as positive controls. The
concentration ofsubstrates was determined nearthe Km values:
estradiolwas50,10,and20μM,propofolwas5,10,100μM,and
zidovudinewas25,100,200μM,respectively.Thereactionrateswere
linearwith incubation timeandmicrosomalprotein contentsunder
theseconditions.DixonandLineweaver-Burkplotswereadaptedto
determinetheinhibition type,and thesecond plotofslopesfrom











were calculated by a non-compartmental analysis (WinNonlin
Professionalver.5.2,Pharsight,Mountain View,CA,USA) for












(LunaC18,50mm ×2.0mm i.d.;3 μm particlesize;Phenomenex,
Torrance,CA) maintained at 40°C.Mobile phase consisted of
acetonitrile(A)andwatercontaining0.1% formicacid(B)ataflow




time was 6 min.An Agilent1260 series high-performance liquid
chromatographysystem (Agilent,Wilmington,DE),wasused.













Forpharmacokinetic study ofginsenosides,we chose API5500
Q-Trap massspectrometer(AB Sciex,FosterCity,CA)equipped
withAgilent1290HPLC system (AgilentTechnologies,Wilmington,
DE) in an electrospray ionization (ESI)mode used to generate
negative [M–H]–. The compounds were separated on a
reversed-phase column (Acclaim RSLC C18 column150 × 2.1 mm,
















Acetaminophen 152.0>110.1 200 46 21 12 Positive 
Oh-coumarin 160.8>132.9 150 -90 -28 -11 Negative
Oh-bupropion 256.3>238.1 150 136 19 18 Positive
Oh-rosiglitazone 373.9>151.1 150 16 33 16 Positive
Oh-tolbutamide 284.9>189.6 150 -20 -42 -11 Positive
Oh-mephenytoin 235.1>150.2 150 56 27 10 Positive
Dextrorpan 258.1>157 150 191 53 12 Positive




200 45 22 39 Positive
Serotonin-O-Glucuronide 353>160 200 34 33 3 Positive
Propofol-O-Glucuronide 353.1>177.1 200 -32 -34 -2 Negative
AZT-5’-Glucuronide 442>125 200 -55 -30 -1 Negative
Clorpropamide 277>175 150 120 20 12 Positive
Clorpropamide 274.9>189.6 150 -80 -50 -12 Negative
Theophylline 181.1>124.1 200 27 40 10 Positive
Theophylline 179.1>163.9 200 -59 -20 -1 Negative
20-ginsenoside Rg3 783.4>161.1 150 -5 -44 -9 Negative
20-ginsenoside Rh2 621.3>161.1 150 -20 -30 -17 Negative








of the corresponding control values using the substrates.The
remaining activitiesatthetestedhighestconcentration lesserthan
80% wereconsideredtobe“positive”andthenthe50% inhibitory
concentration (IC50) values were extrapolated by nonlinear
least-squares regression analysis using WinNonlin (ver. 4.0;
Pharsight,Mountain View,CA,USA).Thekineticparametersfor
inhibitorypotential(Ki)wereinitialyestimatedbygraphicalmethods
such as Dixon plot and Lineweaver-Burk plot,but ultimately
determinedby nonlinearleast-squaresregression analysisfrom the
bestenzymeinhibition modelusing Enzymekineticsoftware.The
mode ofinhibition was determined on the basis ofthe Akaike
information criterion,as a measure ofthe goodness offit.The
inhibition modes tested included pure and partial competitive
inhibition, noncompetitive inhibition, mixed-type inhibition, and
uncompetitiveinhibition.
Pharmacokineticparameterswerecalculatedbyanon-compartmental
analysis using WinNonlin Professional, version 2.1 (Pharsight,
Mointain View, CA, USA): the total area under the plasma
concentration-time curve from time zero to infinity or the last
measured time (AUCt),and terminalhalf-life.The peak plasma
concentration(Cmax)andtimetoreachCmax(Tmax)werereaddirectly
from the experimental data. The results were analyzed using
21
Student’s t-test,with p value < 0.05 considered to statistical


















Table 3.IC50 determination ilustrates the overal CYP inhibitory
effectas a function ofthe testinhibitorconcentration.Samples
containingonlycocktailsubstratesetatthearoundKm valuewere
considered100% activityandalvelocitymeasurementofinhibitor











IC50 (µM) Astaxanthin β-cryptoxanthin Canthaxanthin Lutein Zeaxanthin
CYP1A2 >5 >5 >5 >5 >5
CYP 2A6 >5 >5 >5 >5 >5
CYP 2B6 >5 >5 >5 >5 >5
CYP 2C8 >5 13.8 >5 >5 >5
CYP 2C9 >5 >5 >5 >5 >5
CYP 2D6 16.2 >5 10.9 >5 >5
CYP 2E1 >5 >5 >5 >5 >5








CYP1A2 >20 >20 >20 >20 >20
CYP 2A6 >20 >20 >20 >20 >20
CYP 2B6 >20 >20 >20 >20 >20 
CYP 2C8 17.4 >20 >20 >20 >20 
CYP 2C9 >20 >20 >20 >20 >20
CYP 2D6 >20 >20 >20 >20 >20
CYP 2E1 >20 >20 >20 >20 >20



















Time-dependent inhibition of xanthophyls and fermented
GinsengextractoncytochromeP450activities
Time-dependent inhibition is a term covering any phenomenon




al.2007;Fowlerand Zhang,2008).When the inhibition curveis
shiftedtoalowerIC50valueby30minpre-incubationtreatment,this




IC50 shift for CYP3A4/5 by canthaxanthin with human liver
microsomes.Time-dependentinhibitory effectsofBST204on nine
CYP isozymes also suggested thatthe testcompounds are not
time-dependentinhibitors.
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no inhibitory effecton UGT1A6,UGT1A9 and UGT2B7.But,β
-cryptoxanthin, canthaxanthin and zeaxanthin showed inhibitory
effectson UGT1A1with IC50 values23.68,36.74and 42.57 μM,
respectively,IC50 ofβ-cryptoxanthin and lutein on UGT1A4were
28.66and29.94μM,respectively(Table3).Astaxanthindidnotshow
significantinhibitiononthefivekindsofUGT1A1andUGT1A4.IC50














IC50 (µM) Astaxanthin β-cryptoxanthin Canthaxanthin Lutein Zeaxanthin
UGT1A1 >50 23.68 36.74 >50 42.57
UGT1A4 >50 28.66 >50 24.94 >50
UGT1A6 >50 >50 >50 >50 >50
UGT1A9 >50 >50 >50 >50 >50
UGT2B7 >50 >50 >50 >50 >50
IC50 BST204 
(µg/mL)




UGT1A1 13.80 >100 >100 >100 77.75
UGT1A4 >100 >100 >100 >100 >100
UGT1A6 >100 >100 >100 >100 >100
UGT1A9 24.59 >100 13.65 >100 >100















substrate reaction. Represented by % of control activity. Al
experimentswereconductedasduplicate.
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Ki determination of β-cryptoxanthin, BST204, S-Rg3 on
UGT1A1,1A9,2B7
The Dixon plotand Lineweaver-Burk plotindicated thatchrysin
competitively inhibited themetabolism ofestradiolin HLMs.The
inhibitionkineticparameter(Ki)wascalculatedtobe306.51μM.Like
UGT1A1, niflumic acid, as the positive control, inhibited the
metabolism ofpropofolinthecompetitivemanner,whichindicatedby





ofestradiolin HLMs.The inhibition kinetic parameter(Ki)was
calculatedtobe30.43 μM,whichismuchhighertheCmax ofβ






determination of β-cryptoxanthin towards UGT1A1-mediated
glucuronidation.Altheexperimentswerecarriedoutinduplicate.
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Figure 10.Dixon plotand Lineweaver-Burk plotaboutthe Ki
determinationofBST204towardsUGT-mediatedglucuronidation.(A)





Figure 11.Dixon plotand Lineweaver-Burk plotaboutthe Ki
determination ofginsenoside Rg3 S-form towards UGT-mediated
glucuronidation.(A)GinsenosideRg3S-form on UGT1A9-mediated
estradiol glucuronidation; (B) Ginsenoside Rg3 S-form on

















(g min/mL)b 1.61 ± 0.81 3.38 ± 2.23 
C
max
 (g/mL)c 0.00484 ± 0.00341 0.00693 ± 0.00283
T
max




 (g min/mL) - 73.21 ± 25.89
C
max
 (g/mL) 0.102 ± 0.0582 0.275 ± 0.095
T
max
 (min)    120 120
Table5.PharmacokineticparametersofginsenosideRg3S-form and














The concentration ranges used were based on solubility and the







CYP2C19,CYP2D6,CYP2E1,andCYP3A activitiesin human liver





values for astaxanthin,β-cryptoxanthin,canthaxanthin,lutein and
zeaxanthin were 2.17,0.15,1.4,1.05,and 0.15 μM,respectively
(Østerlieetal.,2000;Breithauptetal.,2003;Paetau etal.,1997;
Granadoetal.,1998;Yuetal.,2012).Theconcentrationrangesofthe
test compounds used covered them.Control samples (with no
inhibitor) were assayed in each analyticalrun.The amountof
metaboliteineachsample(relativetocontrolsamples)wasplotted
versustheinhibitorconcentrationpresenttoeliminatetheimpactof
DMSO.BST204 and ginsenoside Rg3 and Rh2 were soluble in
methanol and we studied the pharmacokinetics of BST204.
Interestingly,Interestingly,we work found that the S epimers
exhibited significantly higherconcentrations and area undercurve
43
valuesforbothRg3andRh2inhumanplasma.TheCmax ofS-Rg3
in human plasmaafteradministrated 100mg and 400mg BST204











with each concentration ranges,on theotherhand,theIC50 were
much more than the highest concentrations of the designed
concentration(exceptBST204inhibitedCYP2C8withIC5017.4µg/ml),
no IC50 shifts ilustrated that al the test compounds had no
drug-interaction with CYPs in the long time and people can
co-administrateitwithotherdrugs(ObachRS,etal.,2007).
Themainpathwayofconjugativemetabolism forawidevarietyof
compounds is glucuronidation by UGTs. Human
UDP-glucuronosyltransferase(UGT)existsasasuperfamily of22
proteins,whicharedividedinto5familiesand6subfamiliesonthe




al therapeutic classes (Rowland et al., 2013). Glucuronidation
elimination pathway in phaseIImetabolitesplaysmoreand more
importantroleinrecentyears.Glucuronidationreactionscatalyzedby
UGT isoformsaccountfor>35% ofal phaseI drug metabolism




vitamins (Burchel etal.,1995;Radominska-Pandya etal.,1999;
Tukey etal.,2000).Sointeraction with UGTsisalsocannotbe
ignored.Fang’sresearch indicated thattheginsenosides'inhibition
towards UGT isoforms might be an important reason for












both in vitro inhibition kinetic parameters (Ki) and in vivo
concentration ofinhibitors.Ifthe maximum plasma concentration
45
(Cmax) were as the [I]in vitro–in vivo extrapolation equation:
AUCi/AUC=1+[I]in vivo/Ki,the ratio ofCmax/Kicould help us to
extrapolatethedrug-drug interactionrelatedtheUGT enzymes.A
pharmacokinetic study reported that a single dose carotenoid




concentration (Cmax)ofS-Rg3 was as the [I]in vitro–in vivo
extrapolationequation:AUCi/AUC=1+[I]in vivo/Ki,theratioofCmax
/KicouldhelpustoextrapolatethatS-Rg3andBST204mayinteract
with UGTs.Butwecannotdraw conclusion basedon itandthe










nutritional supplements alter the pharmacokinetics of drugs
metabolizedby CYPsorUGTs.On theotherhand,furtherstudy
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억제효과에 을 맞춘 xanthophyl과 발효
인삼 추출물의 허 -약물 상호작용의 평가연구
허 보충제와 건강보조식품의 폭넓은 심으로 인해 허 -약물간의
상호작용에 해서도 최근에 많은 주목을 받아오고 있다. 주요
xanthophyl인 astraxanthin, β-cryptoxanthin,canthaxanthin,lutein,
zeaxanthin은 항산화 효과를 가지거나 암 는 노인성 황반변성을 방
하는 역할로 리 사용되고 연구되어 왔다.BST204는 Rh2와 Rg3를 높
은 농도로 함유하고 있던 새로 발효 인삼 추출물이다.Rh2와 Rg3는 가
공하지 않은 인삼에서 ginsenoside-β-glucosidase에 의해 형성되며 산
조건하에서 가수분해를 통해 20(R)/20(S) ginsenoside Rg3 와
20(R)/20(S)ginsenosideRh2이 더 풍부하게 만들어진다.최근 연구에서
이 물질들이 항암효과를 보 다.이 논문의 목 은 사람의 간 효소인
cytochrome P450와 UDP-glucuronyltransferase에 한 다섯 종류의
xanthophyl (astraxanthin, β-cryptoxanthin, canthaxanthin, lutein,
zeaxanthin)과 발효 인삼 추출물 BST204,입체선택성 ginsenosideRg3,
Rh2epimer의 9가지 CYPs,5가지 UGTs에 한 억제효과와 CYPs에
한 유도효과에 상호작용을 평가하는 것이다.
USFDA 가이드라인에 따라 CYP1A2,CYP2A6,CYP2B6,CYP2C8,
CYP2C9,CYP2C19,CYP2D6,CYP2E1와 CYP3A에 한 각각의 기질




선택하 다. Competitive screening을 해 실험물질인, cocktail,
NADPH re-generatingsystem,사람 간 마이크로좀 (HLM)과 함께 5분
동안 pre-incubation 후에 15분간 incubation을 시행하 다.
Time-dependent inhibition 실험도 진행하 다. Test compounds과
HLM을 NADPH유무에 따라 37°C에서 30분간 incubation하 고 이 후
기질 용액에 조 옮겨 15분간 incubation하 다.UGT1A1,UGT1A4,
UGT1A6,UGT1A9와 UGT2B7에 한 각각의 기질로써 β-estradiol
(10μM),trifluoperazine(40μM),serotonin(4000μM),propofol(100μ
M) 와 zidovudine (100 μM) 을 선택하 다. 실험물질과 HLM,
Tris-HClbuffer(pH 7.5),MgCl2 (5mM),substrate,andalamethicin
(25μg/mL)을 30분간 pre-incubation한 후에 UDPCA를 첨가하여 37°C
에서 30분 는 60분간 incubation을 시행하 다.
실험 결과 xanthophyl과 발효 인삼 추출물은 9가지 CYP의 가역 ,
비가역 억제에 해 무시할만한 효과를 보 다. 하지만 β
-cryptoxanthin,canthaxanthin,zeaxanthin은 UGT1A1에 해 각각 IC50
23.68,36.74,42.57μM로 억제효과를 보 다.β-cryptoxanthin,lutein역
시 UGT1A4에 해 억제효과를 보 다. UGT1A1에 한 β
-cryptoxanthin의 Ki는 30.43으로 β-cryptoxanthin의 Cmax보다 훨씬 높
았다.따라서 5가지 xanthophyl은 시험 내에서 UGT에 해 억제효과
를 보이지 않음을 추측할 수 있었다.CYP와 UGT에 한 5가지
xanthophyl의 IC50값은 이미 알려진 장농도에서의 Cmax값보다
하게 큰 값이었다.BST204는 각각 IC50값 13.80,24.59,30.83μM 으로
UGT1A1,1A9,2B7을 억제하 다.S-Rg3는 UGT1A9과 2B7에 해 억
제효과를 보 다.UGT1A1,1A9,2B7효소에 한 BST204의 Ki는 각각
27.38,17.53,32.51μg/mL 다.UGT1A9과 2B7에 한 S-Rg3의 Ki는
59
각각 8.33와 24.89μM 다.
건강보조식품에 포함된 5가지 xanthophyls가 CYP나 UGT에 의해
사되는 약물의 약동학에 향을 주지 않을 것으로 보인다.하지만 발효
인삼 추출물BST204은 UGT1A1,1A9,2B7 한 추가 실험이 필요하다.
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